Connect with us

Cannabis News

Florida appeals court ruling tightens path for adult use cannabis ballot initiative

Published

5 months ago

on

Florida appellate judgment last week It has added another layer of difficulty to efforts to place a recreational cannabis amendment on the state’s November 2026 ballot, reinforcing how narrow and procedural the road to voter initiatives has become in the state.

A three-judge 1st District Court of Appeal sided with state officials in a dispute over the validity of more than 70,000 petition signatures. The court upheld Secretary of State Cord Byrd’s guidelines that allow county election officials to void petitions signed by voters classified as inactive, as well as those collected by out-of-state circulators.

Smart & Safe Florida, the political committee sponsoring the amendment, is working to meet the state’s Feb. 1 deadline. The campaign must submit at least 880062 valid signatures to vote. According to the latest state count, just over 760,000 valid signatures have been verified so far.

© GÜD EssenceJasmine Johnson, CEO of GŪD Essence

Proponents of the measure have argued that the decision increases the already rigorous petition process and increases the chance that voters will again be denied the chance to weigh in on adult-use legalization. However, state officials and opponents say the ruling reflects existing legal requirements and is intended to protect the integrity of the ballot initiative system.

“This decision highlights how complex and procedural Florida’s voting process is, especially when it comes to an issue as highly regulated as cannabis,” said Jasmine Johnson, CEO of GŪD Essence. “Regardless of where one stands on adult use, the ruling underscores that ballot initiatives are being closely scrutinized and that courts continue to delay enforcement of state law requirements.”

According to Jasmine, Florida already operates one of the most restrictive cannabis frameworks in the US, with a limited licensing structure and extensive compliance requirements for medical marijuana treatment centers. Jasmine says the uncertainty surrounding the voting effort reinforces the need for realism among operators and policymakers. “From the perspective of a soon-to-be MMTC operator preparing to enter the Florida market, this moment reinforces some important realities,” he said. “Florida’s cannabis landscape is already one of the most regulated in the country, and any expansion, whether for medical or adult use, will require careful implementation, strong enforcement infrastructure and clear guardrails.”

For industry participants, Jasmine noted that the focus cannot be on a single regulatory outcome. “The uncertainty surrounding the ballot initiative makes it even more important for regulators, policymakers and industry stakeholders to have transparent conversations about how legalization will unfold in practice. For operators building now, the focus is on serving care patients responsibly, investing in compliant facilities, and planning for multiple possible regulatory outcomes rather than assuming a single path forward.”

For more information:
GÜD Essence
https://greenessenceflorida.com

Related Topics:
Continue Reading

Cannabis News

New access solution for cannabis facilities designed to address limitations of traditional gates

Published

5 hours ago

on

June 26, 2026

By











SpaceGuard Products, a North American manufacturer of wire mesh security solutions and security protection systems, has released the BeastWire® Tunnel Door. This access solution is designed to overcome the limitations of traditional balanced doors and is aimed at cannabis cultivation, processing, packaging and distribution environments. The BeastWire Tunnel Door is designed for installations that require vertical clearance, reliable movement and floor space efficiency.

The BeastWire Tunnel Door provides top clearance with no tracks in the operating path of the door. It is suitable for spaces where overhead paths are not feasible, such as facilities that use high-mast forklifts, oversized pallet loads or specialized material handling equipment. Tall equipment can pass through the opening unhindered, allowing for continuous workflow and flexibility in equipment movement.

© SpaceGuard Products

The door uses a track system designed to create consistent movement. This addresses issues such as stuttering, binding, and misalignment that can occur with conventional sliding or counterbalanced designs. The track controls the path of the door so that the locking mechanism aligns with each cycle, allowing operators to close the door with relatively low force.

Unlike lower track systems that require a soil trench, the BeastWire Tunnel Door mounts above ground. This avoids cutting the installation slab, simplifies installation and reduces maintenance requirements. The system can be installed as a retrofit or in new construction, without changing the floor.

© SpaceGuard Products

The door frame and retractable design reduces the need for side supports and additional space on the side of the door. This results in a smaller footprint and more usable surface area. The gate has the same construction approach as other BeastWire systems.

The BeastWire Tunnel Door is a high-access door designed for strength and ease of use in cannabis industry facilities.

For more information:
SpaceGuard products
Email: (email protected)
spaceguardproducts.com/










Continue Reading

Cannabis News

DEA Defends Stance That Synthetic Cannabis Compound HHC Is Federally Banned In Response To Industry Lawsuits

Published

5 hours ago

on

June 26, 2026

By

The Drug Enforcement Administration (DEA) is resisting efforts by two hemp companies to resist the determination that it is a cannabinoid It is illegal synthetically produced from components of the cannabis plant.

The DEA issued a rule last month saying that was already the case made hexahydrocannabinol (HHC) an illegal substance Under the federal Controlled Substances Act (CSA), the agency will now assign the compound its own unique drug code for classification.

That move is being challenged in a series of lawsuits by hemp businesses that say the agency’s decision is “unlawful.”

In addition to filing petitions for review, the companies are also petitioning federal courts to block the agency’s action while the lawsuits proceed.

The DEA, in briefs filed in the cases this week, argued that each applicant “does not meet any of the factors necessary to demonstrate that it should await review.”

“The rule does not affect HHC’s previous status as a Schedule I substance; all it does is list HHC separately and assign it a separate drug code,” the agency’s brief said.

“With or without the final rule, HHC is a controlled substance. Thus, even if this Court stayed the final rule pending review, (companies) would continue to be subject to existing legal and commercial risks for HHC-related actions,” they say, “Contrary, the suspension would undermine the government’s efforts to improve the regulation of HHC, including the permitted amount or approval process for public permits for HHC. Interests also favor a stay, which would create confusion about HHC’s status as a controlled substance.”

HHC can be found in trace amounts in cannabis plants, but it is also synthesized from hydrogenated cannabidiol (CBD). Delta-9 is sometimes sprayed on cannabis flowers that are low in THC, the most well-known psychoactive ingredient in marijuana, and its psychoactive effects are said to be similar.

While the 2018 Farm Bill legalized hemp and its derivatives with less than 0.3 percent delta-9 THC, the DEA says that only applies to naturally occurring cannabinoids, not synthetic ones. Accordingly, the agency’s position is that HHC does not fall within the definition of legal hemp.

One of the pending cases, filed by Bluestar Operations, LLC before the US Court of Appeals for the Fourth Circuit, refers to a prior ruling in that jurisdiction. the hemp-derived cannabinoid THC-O-acetate is federally legal Despite the DEA’s claims to the contrary.

“Congress deliberately used broad statutory language and did not prohibit cannabinoids that are subject to common extraction, refining, conversion, hydrogenation, distillation, or similar manufacturing processes commonly used in the hemp industry,” the complaint states.

The DEA’s move “conflicts with the plain text, structure, and intent of the 2018 Farm Bill and inserts unlawful limitations that Congress neither intended nor enacted,” it says. The agency’s action “has already caused specific and immediate harm to the petitioner, including substantial compliance costs, business uncertainty, reputational damage, disruption of business relationships, and interference with ongoing operations.”

“Congress, not executive agencies such as the DEA, defines the scope of federal criminal liability. The DEA has no authority to curtail Congress’s legalization of hemp-cannabinoids through an interpretive construction that the statutory text does not support.”

Bluestar said in its new response to the DEA’s initial response brief that the agency “cannot defend the merits of treating hemp-derived HHC as a Schedule I controlled substance, which this Court rejected against binding Circuit precedent” in the previous ThC-O-acetate case.

“The respondents have recast the impugned DEA rule as a weightless ‘technical correction’ that harms no one and decides nothing,” he said. “They have then flipped the script by arguing that Bluestar lacks standing to challenge. Respondents can’t have it both ways.”

The other new lawsuit was filed by IHC Investments, Inc. in the U.S. Court of Appeals for the Ninth Circuit, which previously ruled on the federal legalization of hemp through the 2018 Farm Bill. removed the limits on the wide range of molecules produced by the cannabis plant-delta-8 including the psychoactive cannabinoid THC.

The petition states that “the DEA effectively, and therefore unlawfully, attempts to expand federal criminal liability through administrative interpretation that is not supported by the plain statutory text of the enabling legislation.”

“Congress did not prohibit converted cannabinoids, hydrogenated cannabinoids, or cannabinoids subject to common processing techniques,” the complaint states. “Congress did not expressly authorize the DEA to criminalize broad categories of hemp-derived cannabinoids through administrative interpretation.”

Both petitions argue that the DEA’s move last month violates the central question doctrine, which holds that if an agency wants to decide a matter of national importance, that action must be protected by clear authorization from Congress.

The agency’s HHC ban “has enormous economic and political significance affecting the multibillion-dollar nationwide hemp industry,” says the lawsuit brought by Bluestar.

David Sergi, the attorney leading the new Ninth Circuit case for IHC Investments, said in a press release Thursday that the DEA’s action “directly conflicts” with the 2018 federal Farm Bill legalizing hemp and its derivatives.

“The DEA’s ruling has caused immediate and specific harm to hemp businesses across the nation,” he said. “That reclassification has led to immediate cancellation of contracts, loss of banking relationships and potential destruction of important inventory.”

The DEA, for its part, said in a rule it filed last month that “only tetrahydrocannabinols in or derived from the cannabis plant — not synthetic tetrahydrocannabinols — are exempt from regulation as ‘hemp tetrahydrocannabinol.’

“For further clarification, tetrahydrocannabinols produced through chemical conversion, even when considered synthetically produced when derived from hemp for purposes of the CSA, are not classified as ‘tetrahydrocannabinol in hemp'” under the 2018 Farm Bill, the agency said.

The Federal Register notice was not the first time the DEA addressed HHC’s legal status.

In a 2023 letter, Terrance Boos, chief of the DEA’s Drug and Chemical Evaluation Section, wrote: HHC “does not occur naturally in the cannabis plant and can only be obtained syntheticallyand therefore it is not within the definition of hemp”.

The new filing, signed by DEA Administrator Terrance Cole, said, “this rule does not in any way affect the continued status of hexahydrocannabinol as a controlled substance.”

“This action, as an administrative matter, establishes a separate and specific listing of hexahydrocannabinol in Schedule I of the CSA and assigns a DEA drug code to that substance,” he said. “This action will allow the DEA to establish an aggregate production quota and issue individual manufacturing and purchase quotas to DEA-registered manufacturers of hexahydrocannabinol, which were previously issued individual quotas for these purposes under the tetrahydrocannabinol drug code.”

The DEA’s release cited a move it made last year International drug control organizations to add HHC II of the 1971 United Nations Convention on Psychotropic Substances—but the document fails to note that when the Commission on Narcotic Drugs (CND) took the measure, the US was the only country to abstain from voting.

The DEA said the US Department of Health and Human Services (HHS) “conforms to the direct listing and drug code assignment of hexahydrocannabinol in the CSA.”

Meanwhile, under provisions of a large-scale spending bill signed by President Donald Trump late last year, the federal definition of legal cannabis will change in November. If that language does not change or its the effective date has been postponed, as requested by some members of parliamentonly hemp products with a total of 0.4 milligrams of THC per container will remain legal after November 12th.

At the same time, however, the Trump administration is going wider reschedule marijuana under federal lawwith a A DEA hearing on the matter will begin next week.

Read the last one signings in the following cases:

Photo by Mike Latimer.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Good Behavior dispensary applies to open in Yorkville

Published

1 day ago

on

June 25, 2026

By











A cannabis company called Good Behavior is seeking approval from the city of Yorkville, Illinois, to open a dispensary on a 0.93-acre plot along Saravanos Drive, west of South Bridge Street and south of Stagecoach Trail, becoming the latest entrant in a string of cannabis proposals the city has previously rejected. The company has filed a special-use application with the city and is staking its case on the tax revenue a dispensary would generate for Yorkville.

Full details of the application, including projected tax figures, the company’s ownership structure and details of any board discussions, are available to Shaw Local News Network subscribers. The article, reported by Shaw Local News Network’s Joey Weslo and published on June 23, 2026, notes that cannabis companies had previously failed to get city approval before Good Behavior presented its proposal.

The proposed site places the dispensary in a commercial corridor to the south of the city. Good Behavior’s application requires a special use permit from Yorkville before the project can proceed.

Source: local Shaw










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media